ATC Group: C09AA06 Quinapril

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09AA06 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C09 Agents acting on the renin-angiotensin system
3 C09A ACE inhibitors, plain
4 C09AA ACE inhibitors, plain
5 C09AA06 Quinapril

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 15 mg
PAREN - Parenteral 15 mg

Active ingredients in C09AA06

Active Ingredient Description

Quinapril is a potent angiotensin-converting enzyme (ACE) inhibitor. The mode of action of quinapril in humans and animals is to inhibit circulating and tissue ACE activity, thereby decreasing vasopressor activity and aldosterone secretion.

Related product monographs

Title Information Source Document Type  
ACCUPRIL Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/Old
ACCUPRO Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Cyprus (CY)

Finland (FI)

France (FR)

Germany (DE)

Ireland (IE)

Lithuania (LT)

Mexico (MX)

Poland (PL)

Romania (RO)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.